The Inferior Vena Cava Diameter as a Marker of Dry Weight in Chronic Hemodialyzed Patients

Ando, Yasuhiro; Yanagiba, Satoru; Asano, Yoshihide

doi:10.1111/j.1525-1594.1995.tb02292.x

Cited by 83 publications

(62 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…LV volumes were corrected for body surface area to obtain a volume index. The inferior vena cava (IVC) index was measured by B-mode electron-scan ultrasonography and calculated according to previously described methods [10]. In short, the probe was placed at the subxiphoid portion, and the sagittal section of the IVC behind the liver was viewed.…”

Section: Methodsmentioning

confidence: 99%

Angiotensin II Type 1 Receptor Antagonist, Losartan, Causes Regression of Left Ventricular Hypertrophy in End-Stage Renal Disease

Shibasaki

Masaki

Nishiue

et al. 2002

Nephron

View full text Add to dashboard Cite

Left ventricular hypertrophy (LVH) commonly occurs in patients with end-stage renal disease (ESRD) and is an independent risk factor for cardiovascular events. Angiotensin II type 1 receptor (AT1-R) antagonists may be able to reverse LVH independent to the hypotensive effect in the ESRD setting. Thirty chronically hemodialyzed uremic patients with hypertension were randomly assigned to receive the AT1-R antagonist losartan (n = 10), the angiotensin-converting enzyme (ACD) inhibitor enalapril (n = 10), or calcium antagonist amlodipine (n = 10). Left ventricular mass (LVM) index was measured by echocardiography before and 6 months after treatment. The baseline demographic and clinical characteristics did not differ between the three groups. The mean baseline LVM index also did not differ in the three groups. After 6 months of treatment, losartan treatment significantly reduced the LVM index (–24.7 ± 3.2%) than amlodipine (–10.5 ± 5.2%) or enalapril (–11.2 ± 4.1%) therapy. All three groups had a similar decrease in the mean blood pressure with treatment. The plasma angiotensin II concentration increased 5-fold with losartan treatment. In contrast, the plasma angiotension II concentration did not change with enalapril and only increased 2-fold with amlodipine. Thus, the present study indicates that losartan more effectively regresses LVH in patients with ESRD than do enalapril and amlodipine despite a comparable depressor effect between the three drugs.

show abstract

Section: Methodsmentioning

confidence: 99%

Angiotensin II Type 1 Receptor Antagonist, Losartan, Causes Regression of Left Ventricular Hypertrophy in End-Stage Renal Disease

Shibasaki

Masaki

Nishiue

et al. 2002

Nephron

View full text Add to dashboard Cite

show abstract

“…The inferior vena cava (IVC) index was measured by Bmode electron-scan ultrasonography and calculated according to methods described previously (15). In short, the probe was placed in the subxyphoid portion, and the sagittal section of the IVC behind the liver was examined.…”

Section: Recordings and Analysis Of Echocardiographic Datamentioning

confidence: 99%

Impact of the Angiotensin II Receptor Antagonist, Losartan, on Myocardial Fibrosis in Patients with End-Stage Renal Disease: Assessment by Ultrasonic Integrated Backscatter and Biochemical Markers

et al. 2005

View full text Add to dashboard Cite

show abstract

“…In this study, changes in cardiothoracic ratio and IVC were significantly correlated with changes in BNP, but not with changes in ANP. These 2 markers 23,24) as well as BNP 25) have been recognized as good markers of dry weight in HD patients. Although our results were consistent with previous reports, the reason why ANP was not correlated with these markers remains unknown.…”

Section: Lack Of Relationship Between Plasma Bnp Level and Transmitramentioning

confidence: 99%

<b>Relationship Between Doppler Transmitral Flow Velocity Pattern and Plasma Atrial and Brain Natriuretic Peptide Concentrations in Anuric Patients on Maintenance Hemodialysis</b>

Ito¹,

Murai²,

Takada³

et al. 2006

Int. Heart J.

View full text Add to dashboard Cite

SUMMARYPlasma atrial (ANP) and brain (BNP) natriuretic peptide levels were compared to determine if transmitral flow velocity pattern is an instantaneous marker of body fluid balance in anuric patients on hemodialysis (HD).We measured plasma ANP and BNP levels and performed Doppler echocardiography in 38 anuric patients before and after HD. Patients with valvular disease, left ventricular systolic dysfunction having a fractional shortening < 0.3, arrhythmia, or left ventricular hypertrophy were excluded. The relationships between plasma ANP or BNP levels and the transmitral flow velocity pattern were evaluated. We also determined if the magnitude of the decrease in plasma ANP level was related to that in the early peak of transmitral flow velocity (peak E). The mean age of the subjects was 61.1 ± 9.7 years.The ANP level of 213.6 ± 146

show abstract

The Inferior Vena Cava Diameter as a Marker of Dry Weight in Chronic Hemodialyzed Patients

Cited by 83 publications

References 14 publications

Angiotensin II Type 1 Receptor Antagonist, Losartan, Causes Regression of Left Ventricular Hypertrophy in End-Stage Renal Disease

Angiotensin II Type 1 Receptor Antagonist, Losartan, Causes Regression of Left Ventricular Hypertrophy in End-Stage Renal Disease

Impact of the Angiotensin II Receptor Antagonist, Losartan, on Myocardial Fibrosis in Patients with End-Stage Renal Disease: Assessment by Ultrasonic Integrated Backscatter and Biochemical Markers

<b>Relationship Between Doppler Transmitral Flow Velocity Pattern and Plasma Atrial and Brain Natriuretic Peptide Concentrations in Anuric Patients on Maintenance Hemodialysis</b>

Contact Info

Product

Resources

About